What actually changed recently?
The newest psoriasis news is about tablets. Two of them now reach immune targets that used to need an injection. Both are approved already, rather than waiting on a decision. Evidence Evidence Evidence Evidence Evidence
What is known
- Reasonably supported
Sotyktu (deucravacitinib) is taken by mouth, and it acts on the TYK2 part of the immune system. The National Psoriasis Foundation calls it the first tyrosine kinase inhibitor approved for psoriasis, and the first new oral psoriasis medicine in a decade. Its label covers adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Icotyde (icotrokinra) is also a tablet, and it acts on the interleukin-23 receptor. FDA approved it in March 2026 for moderate to severe plaque psoriasis.
What is uncertain
- Depends on you
What that means for you is that a tablet is a route, not a ranking. Approval says a product met the standard for the group its label names. It does not say the product beats another one, or that it suits you. Neither label reports long experience after sale yet.
Questions for your dermatologist
Am I in the group either of these labels describes?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would an oral option change how we think about my plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What are the classes, and how do you read a headline?
Psoriasis medicines are grouped by the immune signal they quiet. The injected groups are TNF, IL-12/23, IL-17 and IL-23. Oral small molecules are the other group, and Sotyktu sits in it. Evidence Evidence Evidence
What is known
- Reasonably supported
A biologic targets the part of the immune system that psoriasis leaves overactive. The American Academy of Dermatology names twelve FDA-approved biologics, given as a shot or an infusion. Clinical guidance summarises response by class at weeks 12 to 16. Anti-TNF medicines reached roughly 49 to 80 per cent PASI 75. Stelara (ustekinumab), the IL-12/23 medicine, reached roughly 66 to 75 per cent PASI 75. IL-17 medicines reached roughly 77 to 91 per cent PASI 90, and IL-23 medicines roughly 70 to 75 per cent PASI 90.
What is uncertain
- Depends on you
What that means for you is that two headline numbers are rarely the same measurement. PASI 75 is a 75 per cent fall in a skin score, and PASI 90 is a steeper bar. The week and the enrolled group move too. How to read psoriasis research as a patient sets out that check. These ranges are a summary of the literature, not one head-to-head trial.
Questions for your dermatologist
Which class does my current treatment belong to?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would a different class change for me, and what would it not?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What is a biosimilar, and what is it not?
A biosimilar is a follow-on version of an approved biologic. FDA clears one only when it is highly similar to the original. Whether a pharmacy or a plan will swap it is a separate question. Evidence Evidence
What is known
- Reasonably supported
FDA describes an approved biosimilar as highly similar to its reference product, with no clinically meaningful differences in safety and effectiveness. That is the approval standard, and it is about the medicine itself. Each biologic still keeps its own label, and its own way of being given as a shot or an infusion.
What is uncertain
- Depends on you
What that means for you is that the standard covers the medicine, not the paperwork. It does not establish that every biologic has a biosimilar. It does not move an indication from one product to another. Substitution, coverage and price sit with your plan and your pharmacy.
Questions for your dermatologist
Is there a biosimilar for the biologic we are discussing?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Who decides whether my pharmacy can switch me to one?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does a news item mean a treatment is available?
Often not yet. A psoriasis headline usually means one of three things. A study is running, a company has filed for review, or a regulator has approved something. Evidence Evidence Evidence
What is known
- Reasonably supported
FDA splits product development into five stages. They are discovery, laboratory research, studies in people, FDA review, and watching the product once it is sold. ClinicalTrials.gov holds study records that sponsors submit, each able to carry a status, entry rules, locations and a contact. The FDA list of novel drug approvals for the year records the date of each approval action.
What is uncertain
- Depends on you
What that means for you is that a listing on ClinicalTrials.gov is not an approval. A record there is not government endorsement, and it is not proof of benefit. Three places settle status: the registry for studies, the FDA approvals list for decisions, and the medicine label for the approved group.
Questions for your dermatologist
Is the medicine in this news story approved, or still being studied?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Where would you look to check where it stands now?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What does this mean for you today?
Bring it to the next visit as a question, not as a plan. A new approval is a reason to talk. It is not a reason to stop the treatment you are on. Evidence Evidence Evidence Evidence
What is known
- Reasonably supported
Each approved label names its own group and its own precautions, so the prescriber is the person to settle fit. The National Psoriasis Foundation lists methotrexate, apremilast, deucravacitinib and acitretin among the oral options discussed in psoriasis care. The same foundation offers a Patient Navigator, described as personalised help getting the treatment you need.
What is uncertain
- Depends on you
What that means for you is that cost and coverage move on their own clock. An approval does not make a medicine covered, stocked or affordable. Prior authorization and step therapy are set out on the psoriasis biologic prior authorization page. Neither label picks an option for one reader.
Questions for your dermatologist
Would a newer option change my plan, or is my current one still the right fit?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would you want to see before we moved me to something else?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that ClinicalTrials.gov is a U.S. government database whose sponsor-submitted study records can include status, eligibility, locations and contacts.
What it does not support
A listing is not government approval, scientific validation, proof of benefit, a completeness guarantee or a determination that a reader qualifies.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the distinction between discovery, preclinical research, clinical research, FDA review and post-market monitoring in U.S. product development.
What it does not support
It is a high-level process overview, not a verdict on a specific emerging therapy, a statement that every research stage succeeds or a substitute for the current product label.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: FDA-approved prescribing information is authoritative for US labeling; it is product-specific regulator-approved labeling, not independent comparative clinical evidence.
What this source supports
Supports the current FDA-approved labeled plaque-psoriasis population, oral route, IL-23 receptor mechanism, and label precautions for Icotyde (icotrokinra).
What it does not support
The label states only “Revised: 3/2026”; it does not establish an exact revision day or the approval-action date. It also does not establish comparative superiority, personal suitability, insurance coverage, mature postmarketing evidence, or a class-wide conclusion. SteadySkin does not reproduce its regimen.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the exact US FDA approval action date for Icotyde (icotrokinra).
What it does not support
The approval list does not establish the full labeled population, comparative superiority, personal suitability, insurance coverage, or postmarketing experience.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports only that the FDA approval-package cover for NDA 220149 records an approval date of March 18, 2026 and identifies the approved indication.
What it does not support
The package does not explain or reconcile why the separate FDA Novel Drug Approvals for 2026 table records March 17, 2026. SteadySkin preserves that one-day discrepancy and does not use either record as evidence for what the other records.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the FDA definition that an approved biosimilar is highly similar to its reference product with no clinically meaningful differences in safety and effectiveness.
What it does not support
It does not establish that every biologic has a biosimilar, transfer an indication between products, choose a product, or determine substitution, coverage, availability, or personal response.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed. It is used only for patient-facing treatment-category context.
What this source supports
Supports patient-facing context that methotrexate, apremilast, deucravacitinib and acitretin are real oral treatment options discussed in psoriasis care.
What it does not support
It does not determine personal suitability, comparative benefit, coverage or a treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. National Library of Medicine (DailyMed)Regulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that Sotyktu (deucravacitinib) is a TYK2 inhibitor. Supports that it binds the regulatory domain of TYK2 rather than the catalytic domain, stabilizing an inhibitory interaction that produces allosteric inhibition of receptor-mediated TYK2 activation and downstream STAT signaling. Supports the moderate-to-severe plaque-psoriasis indication for adults who are candidates for systemic therapy or phototherapy. Supports the separate active-psoriatic-arthritis indication for adults. Supports the caution against combining it with other potent immunosuppressants and against live vaccines during treatment. Supports the recommendation to evaluate for tuberculosis before starting. Supports the precaution against starting during an active or serious infection, including active hepatitis B or C. Supports that no dose adjustment is needed for renal impairment or mild-to-moderate liver impairment. Supports that severe liver impairment is not recommended. Supports the fixed 6 mg once-daily dose with or without food and no titration schedule. Supports the instruction not to crush, cut, or chew the tablet. Supports the PASI 75 response rates at week 16 for deucravacitinib, placebo, and the apremilast comparator arm in both POETYK PSO-1 and PSO-2 trials (PSO-1: 58% vs 13% vs 35%; PSO-2: 53% vs 9% vs 40%). Supports the week 24 PASI 75 rates for deucravacitinib versus the apremilast arm (PSO-1: 69% vs 38%; PSO-2: 58% vs 38%). Supports the infection-risk warning and the herpes zoster reports, including a multidermatomal presentation. Supports the lymphoma reports (0.3 per 100 patient-years) and the creatine-phosphokinase/triglyceride/liver-enzyme monitoring guidance. Supports the plaque-psoriasis trial adverse-reaction rates at week 16 (upper respiratory infection 19.2% vs 14.8% placebo, blood CPK increased 2.7% vs 1.2%, herpes simplex 2.0% vs 0.2%, mouth ulcers 1.9% vs 0%, folliculitis 1.7% vs 0%, acne 1.4% vs 0.2%). Supports that no boxed warning is present on this label.
What it does not support
This label does not report an age, skin-tone, race, or ethnicity breakdown of its plaque-psoriasis trial adverse-reaction rates. It also does not state how often a reaction leads to stopping treatment, or predict an individual reader’s dose or response.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed. It is used only for patient-facing mechanism and treatment-category context.
What this source supports
Supports that Sotyktu is the brand name for deucravacitinib, an oral systemic treatment taken once daily by mouth. Supports that it works similarly to biologics by targeting the TYK2 part of the immune system, reducing the overactive immune response behind psoriasis. Supports that it was the first tyrosine kinase inhibitor approved for psoriasis. Supports that it was the first novel oral therapy for psoriasis in a decade. Supports the plain-language list of common side effects: upper respiratory infection, elevated blood creatine phosphokinase, herpes simplex, mouth ulcers, folliculitis, and acne.
What it does not support
Does not report titration details, PASI or trial-response data, dosing adjustments for organ impairment, or cost. Does not report comparative-effectiveness data against other psoriasis treatments, or assess an individual reader’s risk.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that a biologic specifically targets, or quiets, the part of the immune system that is overactive because of psoriasis. Supports the twelve named FDA-approved biologics (Cimzia/certolizumab pegol, Cosentyx/secukinumab, Enbrel/etanercept, Humira/adalimumab, Ilumya/tildrakizumab, Remicade/infliximab, Siliq/brodalumab, Simponi/golimumab, Skyrizi/risankizumab, Stelara/ustekinumab, Taltz/ixekizumab, Tremfya/guselkumab). Supports that dosing is given as a shot or an infusion, with dosing frequency ranging from twice a week to once every three months. Supports that infliximab specifically requires an in-office or infusion-center IV infusion rather than a self-administered shot. Supports that biologics can stop psoriatic-arthritis joint pain, stiffness, and swelling and prevent it from worsening. Supports the common side effects of upper respiratory tract infection, injection-site skin reaction, flu-like symptoms, urinary tract infection, and headache. Supports that biologics raise infection risk, particularly for people with diabetes, tobacco use, an infection history, or advanced age. Supports that blood tests and tuberculosis testing are typically required before starting, with some patients needing additional tests. Supports that four biologics are FDA-approved for children with moderate-to-severe psoriasis from around age four to six and up, depending on the drug.
What it does not support
Does not report PASI or other trial-response data, a boxed-warning quote for any specific drug, an exact screening protocol, or cost/pricing information. Does not predict an individual reader’s response or risk.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- HealioPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports week 12-16 PASI response ranges by biologic class, summarized from the joint AAD-NPF biologics guideline and related clinical literature. Anti-TNF agents: roughly 49%-80% PASI 75. The IL-12/23 drug ustekinumab: roughly 66%-75% PASI 75. IL-17 agents: roughly 77%-91% PASI 90. IL-23 p19 agents: roughly 70%-75% PASI 90. Supports that brodalumab’s label carries a boxed warning calling for regular evaluation of suicide risk, and that bimekizumab’s current US prescribing information includes a Warning and Precaution for suicidal ideation and behavior. Supports a general statement that TNF-class registries and studies warn that these medicines could potentially increase infection risk.
What it does not support
Is a secondary clinical-guidance summary, not the primary guideline document or a primary trial report itself. Does not report a single head-to-head trial comparing classes on the same PASI threshold, a specific reader’s risk, or cost.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education and its own navigation service, but its editorial and funding independence for this page was not independently reviewed. It is used only for the quoted description of its own Patient Navigator service.
What this source supports
Supports that the National Psoriasis Foundation offers a Patient Navigator. The page describes it as available to "connect with a friendly, experienced Patient Navigator for personalized help getting the treatment you need."
What it does not support
Does not report specific manufacturer copay-program terms, patient-assistance-program eligibility, or pricing for any named biologic. Does not guarantee outcome or eligibility for a specific reader.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.